A consortium of translational stem cell and stroke experts from multiple academic institutes and biotechnology companies, under the guidance of the government (FDA/NIH), is missing. Here, we build a case for the establishment of this consortium if cell therapy for stroke is to advance from the laboratory to the clinic.
The Stroke Therapy Academic Industry Round table in our consortium, we outline below the major goals of the STEPS consortium that are deemed critical to move (STAIR) criteria serve as a guide for translation of drug development programs in an attempt to improve the suc-forward the theme of translational cell therapy in stroke.
A major translational research question is determining cess of clinical trials of neuroprotective drugs. However, a preclinical stroke consortium approach remains to be the "go, no-go" criteria to declare whether cell therapy is efficacious in stroke. If we set the bar too low, would created in drug development programs that will include an active collaboration among academia, the pharmaceu-this behavioral recovery in an animal model of stroke translate into clinically relevant functional improve-tical industry, FDA, and NIH. Recognizing that such a vital translational gap between the laboratory and the ment? Similarly, if we set the bar too high, we may be eliminating the potential of a cell-based therapy to pro-clinic also plagues the neurorestorative cell therapy program in stroke, we formed the Preclinical STEPS (Stem vide small and incremental, but meaningful, daily life activity to the patient. Our position is that cell therapy cell Therapeutics as an Emerging Paradigm in Stroke) Consortium consisting of three preclinical stem cell-does not equate to a magic bullet, but we must detect amelioration of experimentally stroke-induced behav-stroke expert laboratories interfaced with a data coordination center and guided by a clinical advisory board.
ioral deficits that have significant clinical relevance. Based on our experience in transplanting bone marrow Our consortium represents a prototype patterned after NIH's recent RFA on the establishment of Preclinical cells in stroke animals, a significant behavioral improvement was detected based on each individual behavior Stroke Consortia, specifically advancing the novel concept of a multiple preclinical stroke laboratory testing of test score and the observed relative improvement was consistently over than the 25% criterion. Moreover, a the efficacy and safety of stem/progenitor cells that echoes both STEPS and STAIR translational crux.
review of the literature reveals that the 25% level or better is consistently used as the criterion of behavioral As we solicit the participation of the FDA and NIH 692 CHOPP ET AL. recovery from stroke (1-4). Our previous communica-sheep and dogs, in parallel with the NHP will help bridge the gap between laboratory data in rodents and tions with the FDA and NIH support this level of behavioral recovery. These observations formed the basis for human applications. In parallel to demonstrating safety and efficacy of employing a 25% or better behavioral improvement criterion. We note, however, that a battery of tests over cell therapy in two species is the requirement for testing the experimental treatment in two stroke models. The a single test provides a more solid characterization of behavioral recovery, but this presents as an additional prevailing notion in animal stroke modeling is that the pMCAo model stands as "a more stringent stroke gating item in that the number of tests reaching the 25% criterion needs to be factored in determining a positive model" than the tMCAo model. Opponents of this view have raised valid questions. First, it is not at all clear or negative outcome. A composite score, similar to an NIH stroke rating scale, incorporating the scores from whether humans suffer a form of stroke similar to permanent nylon filament MCAo. It is clear that there is each task, may aid in interpreting the results from a battery of tests.
residual flow around all human strokes other than lacunes. Along this line of argument, human stroke is al-An equally translational research criterion is the need for evaluation of cell therapy in at least two species, ways a combination of total and partial flow arrest. Second, most large vessel occlusions recanalize with or namely mice and rats, which completely adheres to STAIR and STEPS guidelines. But are mice and rats without exogenously supplied rt-PA. Thus, if cell transplantation would target a delayed poststroke time frame different enough to be considered different species? If we apply the definition of species as a group of related (days, weeks, or months after injury), most humans would have reperfused. Third, other than satisfying arbitrary, individuals or populations that are potentially capable of interbreeding and producing fertile offspring, then the unvalidated sets of Delphi panel guidelines, the rationale for pursuing both tMCAo and pMCAo models would conclusion is that mice and rats belong to different species as they cannot interbreed. Additionally, mice and appear not fully justified. Although many panels have written that tMCAo models could/should be comple-rats exhibit major differences in genetic, reproductive, developmental, morphological, and anatomical features.
mented with pMCAo models, there is no validation of this statement. The preceding concerns resonate a long-Of particular interest is that rats and mice can exhibit different inflammatory responses to the same stimuli, standing issue about limitations of animal modeling in stroke. Our consortium views that the stroke model which could have significant effects on the ability of cell transplantation to work in the two species. For example, needs to focus on focal ischemia, including cortical and cortical plus basal ganglia stroke models. Emphasis is the pathogen/cell killing potential of the complement protein complex C5b-9 is very different in rats and mice given on clearly delineating the focal brain region damaged by stroke, which will be the basis for choosing the (5), which could have significant consequences on the survival and function of the transplanted cells. Assum-appropriate behavioral tests. Although different types of surgical approaches are available, the "end-point" rather ing that the two species only differ slightly, the alternative option may be to pursue a nonhuman primate (NHP) than the "technique employed" is deemed critical in producing the stroke in that the resulting pathophysiologic stroke model. Indeed, such testing of cell therapy in NHP was given much consideration in STEPS, but the manifestations of each stroke model should mimic the human disease condition. The pMCAO approach is cho-consensus from these proceedings is a resounding conclusion that to date the NHP model remains to be vali-sen to provide a model with a severe injury, more severe than the tMCAO model. It should be pointed out that dated for cell therapy and thus is not appropriate at this time for the present proposal. The use of normal, as op-even in a suture pMCAO model there is some collateral blood flow that gets into the infarct. The blood flow is posed to stroke, monkeys may be a feasible alternative, in that one can do a straight toxicology study. However, not zero as blood is supplied via collaterals. While the approach to complement tMCAO with pMCAO has not while such approach will provide partial "safety" and "toxicology" issues, the obvious difference between been validated, one would then have to argue that all preclinical work suffers from the same limitation as we stroke and nonstroke "normal" pathology will remain a major hurdle in providing insights on stroke pathology still do not have validation of the STAIR and STEPS criteria. Nevertheless, expert and consensus panels have and stem cell functionality. Accordingly, validation of NHP stroke model is required prior to employing this come up with these guidelines and our research team is following these guidelines until we have better valida-animal model for testing cell therapy. Of note, a new NINDS RFA is forthcoming that solicits grant applica-tion. The proposed strategy in our consortium to pursue such pMCAo model to complement the tMCAo model tions for the development of an NHP stroke model. Stroke validation studies in other large animals, such as will provide the validation of this approach. Of note, a Stroke Consortia. The STEPS consortium is distinct from
